Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XPF-005 (XEN801) in Healthy Volunteers and Acne Vulgaris
NCT02656043Phase 2Completed
- Sponsor
- Xenon Pharmaceuticals
- Start
- Sep 2015
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acne vulgaris comparing XPF-005 with Vehicle gel (2 arms). Primary endpoint: Change from Baseline in acne lesion count at 12 weeks. Started Sep 2015; status: completed.
02
Drugs
XPF-005
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT02656043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02656043.